Skip to main content
OpenTrials
Completed

NCT Number: NCT06082375

Supplementation With Vitamin D3 on Chronic Low Back Pain Patient

The study was designed as a randomized double-blind placebo-controlled clinical trial with 8-week Vitamin D3 and physical activity intervention. The protocol was approved by Independent Bioethics Committee for Scientific Research at Medical University of Gdańsk (No. 525/2018), in accordance with the Declaration of Helsinki. We enrol 40 patient (aged ≥ 35), Patients diagnosed with chronic pain in the lumbar spine, qualified for surgical treatment at the Department of Neurosurgery Medicinal Unit in Gdańsk. Participation in the study was voluntary, and the condition for participation was obtaining informed consent from the patient.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Low-back Pain

Age range

30 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Medical University

Gdansk, Pomeranian Voivodeship, 80-210, Poland

About this study

Before starting supplementation, a blood sample was taken from patients to determine the status of vitamin D3, measurements of hydroxylated vitamin D at position 25 (25OHD3) and monitoring of inflammatory markers such as Interleukin-6; TumorNecrosisFactor-α. This measurement was performed in the University laboratory in Gdańsk according to a standard, generally accepted method for the determination of a given compound. The blood sample was taken by a qualified nurse. This measurement was repeated to control vitamin D levels and markers of inflammation:

  • After 6 weeks of supplementation (before surgery);
  • After 2 weeks of supplementation (after surgery);

Patients was supplemented with vitamin D or placebo for 6 weeks before surgery and was continue supplementation for 6 weeks after surgery. According to the value of the Body Mass Index, the dose of vitamin D will be appropriately selected for each group:

  • Group 1 BMI 19-25 - 4000 IU
  • Group 2 BMI 25-29,9- 6000 IU
  • Group 3 BMI >30- 8000 IU

A person was appointed to coordinate the allocation of patients to the two groups. Patients was not informed whether they are receiving vitamin D or a placebo. The treating doctors, radiology specialists and the rest of the team was not know what group the patient is in. Within individual groups, patients was randomly assigned to:

  • Group A - patients supplemented with placebo;
  • Group B - patients supplemented with vitamin D3; Patients was informed about the purpose of the research and was receive. The patients diet was monitored during supplementation by a certified clinical dietitian using food diaries. The food diary is a basic tool for monitoring the diet of test subjects. After appropriate training, the respondents are able to fill in the diary on their own, writing down all the meals eaten during the day and snacks with drinks. It is a qualitative and quantitative method that allows you to analyze the diet so far and draw appropriate conclusions.

Patients from both groups who will not have contraindications to exercise, 2 weeks after surgery, was divided into a group for 6 weeks of home routine physical activity and a group not doing any additional physical activity.

  • Group A1 - placebo supplementation + exercise
  • Group A2 - placebo supplementation + no exercise
  • Group B1 - supplementation with vit. D + exercises
  • Group B2 - supplementation with vit. D + no exercise

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pain in the lumbar spine that lasts more than 6 months (diagnosed by signs and symptoms, and tests such as magnetic resonance imaging (MRI));
  • Failure to respond to medications and physical therapies;
  • Visual Analog Pain Scale (VAS), (0-100) score greater than or equal to 50;
  • Numerical Rating Scale (NRS);

Exclusion criteria

  • Rheumatoid arthritis;
  • Diagnosed mental illness;
  • Drugs;
  • Metabolic bone diseases (hypo or hyperparasitism);
  • Chronic kidney diseases and diseases affecting vitamin D metabolism (stomach surgery, chronic liver diseases, kidney failure, malabsorption disorders, systemic infection, tumors, etc.)
  • Medicines that alter the metabolism of bones such as corticosteroids or bisphosphonates;
  • Vitamin D supplements in the last 3 months;
  • BMI: less than 19;

Treatment and study plan

Vitamin D

Dietary Supplement

Vitamin D3 in the form of cholecalciferol.

Other names: cholecalciferol

Placebo

Dietary Supplement

Vegetable oil.

Primary outcomes

  1. Change in vitamin D3 status at blood serum

    Time frame: Baseline and Week 8

    Blood sample will be taken from patients to determine the status of vitamin D3, measurements of hydroxylated vitamin D at position 25 (25OHD3)

  2. Change in vitamin Interleukin-6 status at blood serum

    Time frame: Baseline and Week 8

    Blood sample will be taken from patients to determine the status of interleukin-6, measurements to show changes in inflammation in the blood.

  3. Change in vitamin TumorNecrosisFactor-alfa status at blood serum

    Time frame: Baseline and Week 8

    Blood sample will be taken from patients to determine the status of Tumor Necrosis Factor, measurements to show changes in inflammation in the blood.

  4. Change in cognitive test Quality of life Short Form-36 questionnaire

    Time frame: Baseline and Week 8

    Validated cognitive tests assessing patients' quality of life. The Short Form - 36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

    The eight sections are:

    • vitality
    • physical functioning
    • bodily pain
    • general health perceptions
    • physical role functioning
    • emotional role functioning
    • social role functioning
    • mental health or emotional wellbeing

  5. Change in cognitive test Chalder Fatigue Questionnaire

    Time frame: Baseline and Week 8

    Validated cognitive tests assessing patients' quality of life.

    The subject answers the questions using a 4-step scale (choosing between "better than usual," "no more than usual," "worse than usual" and "much worse than usual"). Answers to the first 7 items give an insight into the intensity of the physical fatigue and the next 4 give a picture of the mental fatigue. The overall score is obtained by adding all the items. There are 2 scoring systems:

    • a Likert system, where the subject's answers are evaluated by awarding 0, 1, 2 or 3 pts, giving a maximum of 33 pts;
    • a bimodal system, which ignores the severity of responses and categorizes the answers as a "problem" ("more than usual" and "much more than usual" - 1 pt) or "no problem" ("less than usual" and "no more than usual" - 0 pt), giving a maximum of 11 pts.

  6. Change in functional test Up&Go

    Time frame: Baseline and Week 8

    Up&Go Test aimed at checking the task completion time as a functional element. Patients wear their regular footwear and can use a walking aid, if needed. Begin by having the patient sit back in a standard arm chair and identify a line 3 meters, or 10 feet away, on the floor.

    For password: "Go," the patient begins:

    • Stand up from the chair. 2. Walk to the line on the floor at your normal pace.
    • Turn. 4. Walk back to the chair at your normal pace. 5. Sit down again. On the word "Go," begin timing. Stop timing after patient sits back down. Record time: time in Seconds.

Sponsors and collaborators

Lead sponsor

Medical University of Gdansk

Other

Registry information

Official study title

Effect of 8-week Supplementation With Vitamin D3 on Functional and Cognitive Performance in Patients With Chronic Low Back Pain Eligible for Neurosurgery Intervention

Important dates

Study start
2019
Primary completion
2021
Study completion
2022
First posted
Oct 13, 2023
Registry last updated
Oct 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.